Biochemistry

Microfluidic Devices Patent Monitoring Service 2024: Coverage of the 150 New Patent Families Published Each Month - ResearchAndMarkets.com

Retrieved on: 
Monday, February 19, 2024
Managed Care, Research, Technology, Medical Devices, Hospitals, Health Technology, Science, Engineering, Medical Supplies, Other Technology, Health, Other Science, Manufacturing, Microfluidics, BOSCH, Biotechnology, POC, Chemistry, Invention, Growth, Nanotechnology, HP, IC, Physics, Patent, Microsoft Excel, IP, Q&A, DNA, Biochemistry, Generic drug

In this broad technical area, more than 20,000 patent families related to microfluidics have been published worldwide, and over 150 new patent families are published each month.

Key Points: 
  • In this broad technical area, more than 20,000 patent families related to microfluidics have been published worldwide, and over 150 new patent families are published each month.
  • The microfluidic devices patent monitoring service allows you to take advantage of a monthly updated Excel file and benefit from both quarterly analysis reports and direct interaction with our analysts.
  • This useful Excel patent database allows for multi-criteria searches including priority date, patent assignees, claims, legal status of patents and technology segments.
  • Main patent applicants and their inventions, blocking patents, promising patents and key patents newly expired or abandoned will be highlighted.

"Double Life" of Key Immune Protein Reveals New Strategies for Treating Cancer and Autoimmune Diseases

Retrieved on: 
Friday, March 8, 2024
Bangladesh Technical Education Board, University of Oslo, Cancer, University, The central science, Immune system, Research, Doctor of Philosophy, Science Immunology, National Institutes of Health, MD, Moses Austin, Neoplasm, Inflammation, Wang, Wellcome Trust, Rheumatology, Lupus, PD-1, Bristol Myers Squibb, Howard Hughes Medical Institute, Biochemistry, NYU, Autoimmunity, Perlmutter, Rheumatoid arthritis, Pathology, Ligand, Pharmacology, NYU Langone Health, Patient, Hanmi Pharmaceutical, Internal medicine, Biomedical sciences, Funding of science, Columbia University, Mouse, Vaccine

The same findings also support experimental treatment strategies for autoimmune diseases, in which the immune system attacks the body, because stimulating the action of PD-1, as opposed to restricting it, can potentially block an overactive immune response.

Key Points: 
  • The same findings also support experimental treatment strategies for autoimmune diseases, in which the immune system attacks the body, because stimulating the action of PD-1, as opposed to restricting it, can potentially block an overactive immune response.
  • The study results revolve around the body's immune system, which is primed to attack virally infected and cancerous cells while leaving normal cells alone.
  • The immune system recognizes tumors as abnormal, but cancer cells can hijack checkpoints to turn off immune responses.
  • At the same time, PD-1 signaling is slowed in autoimmune diseases like rheumatoid arthritis, lupus, and type 1 diabetes, such that the action of unchecked immune cells creates inflammation that can damage tissues.

UT Health San Antonio secures $16.4 million from CPRIT over six months, adding transformative expertise, bolstering cancer research

Retrieved on: 
Friday, March 8, 2024
Doctor of Philosophy, Education, MD, Drug development, DNA repair, National Cancer Institute, Breast, University, RNA, Research institute, Ovarian cancer, Cell Systems, Health, Genetics, Anatomy, Biochemistry, Bangladesh Technical Education Board, Algorithm, Adolescence, Nursing, Neoplasm, Kitagawa, Faculty, Dentistry, HPV, Child, DNA, Chromatin, Therapy, SAN, National Institutes of Health, Mentorship, Chromosome instability, Doctor of Pharmacy, Structural biology, Vaccination, Cancer Research Institute, Molecular medicine, News, Laboratory, Research, University of Texas System, Cedars-Sinai Medical Center, Survivor, BRCA2, Cell, Howard Hughes Medical Institute, School, Cancer prevention, Luan, BRCA1, Patient, Teaching, Ewing sarcoma, Cancer, Public, Vaccine

SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) (https://uthscsa.edu/) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas (https://www.cprit.state.tx.us/about-us) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.

Key Points: 
  • SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) ( https://uthscsa.edu/ ) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas ( https://www.cprit.state.tx.us/about-us ) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.
  • The Mays Cancer Center at UT Health San Antonio ( https://cancer.uthscsa.edu/ ) is one of only four National Cancer Institute-designated Cancer Centers in Texas.
  • The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas.
  • The Greehey Children's Cancer Research Institute ( https://cancer.uthscsa.edu/gccri ) is one of only two institutes in the United States dedicated solely to pediatric cancer research.

A Global Milestone in Innovative Pancreatic Cancer Therapy

Retrieved on: 
Thursday, March 7, 2024
Bangladesh Technical Education Board, Cancer, Cachexia, Toxicity, Anemia, Multimedia, Cell proliferation, NIH, Molecular biology, Pancreatic cancer, FDA, Quality of life, Animal, Drug development, Growth, Gallbladder, Metastasis, Nausea, Peripheral neuropathy, Argyreia nervosa, Lung, Breast, Stomach, Life expectancy, Leukemia, Patient, Paclitaxel, Survival, Diagnosis, Research, BGX, Biochemistry, Pharmaceutical industry

TAIPEI, March 6, 2024 /PRNewswire/ -- BioGate Precision Medicine Corp., a member of Powerchip Group, held a press conference today to unveil an innovative breakthrough in pancreatic cancer drug development. Dr. Frank Huang, Chairman and CEO of BioGate, revealed that BioGate through in-house R&D has created a targeted therapy biologic, BGX. This was achieved by developing multi-platform technology combining biochemistry, immunology, and molecular biology. Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates. This achievement represents a major global milestone in pancreatic cancer treatment. BioGate also announced its plan to apply for TFDA Phase I clinical trials and to seek approval from the U.S. FDA, offering hope and improved care for pancreatic cancer patients in Taiwan region as well as worldwide.

Key Points: 
  • Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy developed in-house by BioGate.
  • Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates.
  • This achievement represents a major global milestone in pancreatic cancer treatment.
  • In studies of animals implanted with human cancer cells, BGX successfully inhibited the growth and spread of pancreatic cancer cells and prolonged survival rates.

A Global Milestone in Innovative Pancreatic Cancer Therapy

Retrieved on: 
Thursday, March 7, 2024
Bangladesh Technical Education Board, Cancer, Cachexia, Toxicity, Anemia, Cell proliferation, NIH, Molecular biology, Pancreatic cancer, FDA, Quality of life, Animal, Drug development, Growth, Gallbladder, Metastasis, Nausea, Peripheral neuropathy, Argyreia nervosa, Lung, Breast, Stomach, Life expectancy, Leukemia, Patient, Paclitaxel, Survival, Diagnosis, Research, BGX, Biochemistry, Pharmaceutical industry

TAIPEI, March 7, 2024 /PRNewswire/ -- BioGate Precision Medicine Corp., a member of Powerchip Group, held a press conference today to unveil an innovative breakthrough in pancreatic cancer drug development. Dr. Frank Huang, Chairman and CEO of BioGate, revealed that BioGate through in-house R&D has created a targeted therapy biologic, BGX. This was achieved by developing multi-platform technology combining biochemistry, immunology, and molecular biology. Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates. This achievement represents a major global milestone in pancreatic cancer treatment. BioGate also announced its plan to apply for TFDA Phase I clinical trials and to seek approval from the U.S. FDA, offering hope and improved care for pancreatic cancer patients in Taiwan region as well as worldwide.

Key Points: 
  • Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy developed in-house by BioGate.
  • Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates.
  • This achievement represents a major global milestone in pancreatic cancer treatment.
  • In studies of animals implanted with human cancer cells, BGX successfully inhibited the growth and spread of pancreatic cancer cells and prolonged survival rates.

VGXI Welcomes Michael Stewart as New Chief Operating Officer

Retrieved on: 
Monday, March 4, 2024
Engineering, DOD, Chemistry, Growth, Hospital, Retirement, GMP, Child, University, CDMO, Doctor of Philosophy, RNA, Organization, Fujifilm Diosynth Biotechnologies, University system, Consciousness, Research, DNA, St. Jude's, Biochemistry

CONROE, Texas, March 4, 2024 /PRNewswire/ -- VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and RNA medicines, proudly announces the appointment of Michael Stewart as its new Chief Operating Officer (COO).

Key Points: 
  • CONROE, Texas, March 4, 2024 /PRNewswire/ -- VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and RNA medicines, proudly announces the appointment of Michael Stewart as its new Chief Operating Officer (COO).
  • Stewart brings over 20 years of extensive experience in the viral vector therapy and vaccine production industry, which will be instrumental to VGXI's continued growth and success.
  • "We are thrilled to welcome Michael Stewart to VGXI as our new Chief Operating Officer," said VGXI's CEO, Young Park.
  • Please join VGXI in extending a warm welcome to Michael Stewart as he assumes his new role as Chief Operating Officer, effective immediately.

Desta and The Great Mystery

Retrieved on: 
Monday, February 26, 2024
SAN, Desta, Wakan Tanka, Education, Kirkus Reviews, Magic, Hope, Health, Fear, San Francisco Bay Area, Yale University, Economics, Research, Biochemistry, Book

SAN JOSE, Calif., Feb. 26, 2024 /PRNewswire/ -- Today, Falcon Press International announces the release of Getty Ambau's fifth volume of the Desta novel series, Desta and The Great Mystery.

Key Points: 
  • SAN JOSE, Calif., Feb. 26, 2024 /PRNewswire/ -- Today, Falcon Press International announces the release of Getty Ambau's fifth volume of the Desta novel series, Desta and The Great Mystery.
  • After high school, Desta was set to study medicine in Bulgaria and search for the shekel.
  • A friend hastily finds him the college and the benefactors, and Desta travels westward across the globe from Ethiopia to America.
  • "Desta and the Great Mystery, together with the previous four installments of the Desta series, constitute must-read, first-class literature."

MEMS in the Global Medical Market: New Report with 2020-2023 Data, CAGR Projections to 2028 and Profiles of Leading Players TE Connectivity, STMicroelectronics, Teledyne Dalsa and Silex Microsystems

Retrieved on: 
Thursday, February 22, 2024
MEMS, Ophthalmology, Regeneration, Drug, DDS, Toxicity, USD, Pressure, Silicon, Intelligence, Permeability, Temperature, Immunology, Cardiology, Honeywell, Growth, Polymer, Teledyne DALSA, ESG, Endocrinology, TE Connectivity, STMicroelectronics, Administration, Glass, Metal, Microelectromechanical systems, Route of administration, Solubility, Proteomics, LOC, Genomics, Diagnosis, Research, Biochemistry

DUBLIN, Feb. 22, 2024 /PRNewswire/ -- The 'Microelectromechanical Systems (MEMS) in Global Medical Markets' report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 22, 2024 /PRNewswire/ -- The 'Microelectromechanical Systems (MEMS) in Global Medical Markets' report has been added to ResearchAndMarkets.com's offering.
  • Of these, microfluidic and LOC devices account for the largest segment of the MEMS device market.
  • In terms of microfluidic devices, the key potential lies in developing cartridges that are highly sensitive, multichannel and multiplexing systems.
  • Competitive intelligence related to leading companies, their global rankings, recent developments, key financials and segmental revenues, and product portfolios
    Profiles of the leading market players, including TE Connectivity, Honeywell International Inc., STMicroelectronics, Teledyne Dalsa, and Silex Microsystems

Communities In Schools Announces Donna Weiss as New National Board Chair

Retrieved on: 
Wednesday, February 21, 2024
Student, Partnership, Culture, Growth, Harvard University, Government, Pulse, Communities In Schools, Human, Brown University, Strategic planning, Policy, Creative Artists Agency, CIS, Heart, Chair, Community, Biochemistry, Management

ARLINGTON, Va., Feb. 21, 2024 /PRNewswire-PRWeb/ -- Communities In Schools® (CIS®), the nation's leading provider of K-12 school-based integrated student supports, announced today that Donna Weiss has been elected as Chair of its Board of Directors. The Communities In Schools National Board exists to advise CIS' CEO and leadership team on strategy, policies, and practices to ensure the execution of the national office strategic plan, driving system-level change.

Key Points: 
  • ARLINGTON, Va., Feb. 21, 2024 /PRNewswire-PRWeb/ -- Communities In Schools® (CIS®), the nation's leading provider of K-12 school-based integrated student supports, announced today that Donna Weiss has been elected as Chair of its Board of Directors.
  • "Donna Weiss has the voice and vision that can support the CIS National Network from the ground up," said Rey Saldaña, President and CEO of Communities In Schools National Office.
  • "Having served Communities In Schools for close to two decades as a National Board member and previously as a board chair at Communities In Schools of Los Angeles, Donna understands the pulse of our work happening inside schools and has the experience and heart to lead the organization into its next phase of impact."
  • Wynn has been a member of the national board of Communities In Schools since 1999 and was elected chair in 2007.

Europe Laboratory Information Management System (LIMS) Market Insights Report 2023-2028: Rise in Remote Access Needs Boosts Cloud-Based LIMS Adoption Across Europe

Retrieved on: 
Friday, February 16, 2024
LIMS, Growth, Abbott Informatics, LabVantage, Safety, Health, Genetics, Automation, Laboratory, Research, DNA, Pressure, Biochemistry, Fine chemical

DUBLIN, Feb. 16, 2024 /PRNewswire/ -- The "Europe Laboratory Information Management System (LIMS) Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 16, 2024 /PRNewswire/ -- The "Europe Laboratory Information Management System (LIMS) Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • This report offers market size & forecast data for the Europe laboratory information management system (LIMS) market.
  • The laboratory information management system (LIMS) is a software-based laboratory and information management system which supports modern laboratory operations.
  • Who are the key players in the Europe laboratory information management system (LIMS) market?